

CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 29 August 2024

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

CLINUVEL delivers 16% NPAT increase DRIVEN BY REVENUE GROWTH & COST MANAGEMENT

Key Highlights, Year Ending 30 June 2024

Consolidated Entity	30 June 2024	30 June 2023	Change YOY
Total Revenues	\$95,306,000	\$82,990,000	15%
Total Expenses	\$44,627,000	\$37,412,000	19%
Net Profit before income tax	\$50,679,000	\$45,579,000	11%
Net Profit after income tax expense	\$35,636,000	\$30,605,000	16%
Cash Reserves	\$183,868,000	\$156,814,000	17%
Basic Earnings per Share	\$0.72	\$0.62	15%
Net Tangible Assets backing per Share	\$4.02	\$3.29	22%
Dividend distribution per Share	\$0.05	\$0.05	Stable

All figures are reported in Australian dollars for the financial years ending 30 June.
Total Revenues include interest and other income.
Cash Reserves equal Cash and Cash Equivalents plus Cash Held on Term Deposit.
Refer to the Appendix 4E Preliminary Final Report released to the Australian Securities Exchange for details.


CLINUVEL is delighted to report an annual profit after income tax of \$35.6 million for the fiscal year ending 30 June 2024 (FY2024), representing a 16% increase compared to the previous year. This strong performance was primarily driven by increased demand for the innovative drug SCENESSE® (afamelanotide 16mg), which contributed to a 15% rise in total revenues, reaching \$95.3 million for FY2024.

"Throughout the financial year, our team has maintained a sharp focus on executing CLINUVEL's expansion strategy" CLINUVEL's Chief Financial Officer, Mr Peter Vaughan said. "Despite the increased operational complexity, we have remained aligned with long-term objectives and successfully achieved our annual targets. Key financial metrics—including revenue, profit, investment, and asset growth—continue to show consistent year-on-year increases whilst expanding the ability to provide SCENESSE® treatment to an increasing number of patients."

"We are also pleased to announce that the Board has declared a seventh consecutive annual dividend reflecting an ongoing commitment to delivering value to our shareholders in acknowledgement of their steadfast support," Mr Vaughan added.


Profitability and Financial Strength

CLINUVEL has achieved eight consecutive years of profitability, driven by robust annual revenues growth (CAGR 38%) and disciplined expense management (CAGR 20%). For FY2024, net profit before income tax (NPBT) increased by 11% to \$50.7 million.



Over this period, CLINUVEL has evolved by integrating critical operational functions in-house, including commercial distribution, regulatory compliance, product and clinical R&D, and communications, branding & marketing. The Company’s commitment to investing in R&D and expanding corporate capacity is reflected in the five-year expenses plan of \$175.0 million to 30 June 2025. On completion of the fourth year to 30 June 2024, \$125.2 million (or 72%) of the plan, excluding expenses on Communications, Branding & Marketing, has been expended.

Positive annual net cash inflow from commercial operations has seen CLINUVEL’s cash reserves build to a level sufficient to enable the Company to self-finance its diversification plans and provide a buffer to insure itself against the risks of a volatile economic environment. Cash reserves increased by \$27.1 million (17%) during FY2024 to \$183.9 million, up from \$156.8 million in FY2023.



Seventh Consecutive Annual Dividend

The CLINUVEL Board has declared its seventh consecutive annual franked dividend of \$0.05 per ordinary share following the FY2024 financial results. The Company has previously declared dividends for the financial years ending 30 June 2023 (franked of \$0.05), June 2022 (franked of \$0.04) and 2021, 2020, and 2019 (unfranked of \$0.025) and 2018 (unfranked of \$0.02), respectively. Subject to the Company maintaining sufficient cash reserves, the key dates for the dividend are:

- I. Ex-dividend date: 05 September 2024;
- II. Record date: 06 September 2024; and
- III. Payment date: 20 September 2024.

Dividends are available to both Australian and overseas registered shareholders, including holders of CLINUVEL's Level 1 American Depositary Receipts program. Prior to the record date, shareholders are encouraged to confirm their shareholder information, including payment election details, with the Company's share registry – Computershare.

Clinuvel Briefing

CLINUVEL will host an investor and analyst webinar on the FY2024 results at 18:00 AEST today. Participants can register using the link below:

INVESTOR WEBINAR

29 August 2024,
18:00-18:30 AEST (10:00-10:30 CEST)

To participate, please register using this link:
[CLINUVEL Investor Webinar](#)

Questions may be tabled before the webinar,
as you register, and during the webinar.

Questions will be grouped into themes with priority given
to questions submitted before the webinar.

– END –

CLINUVEL's Appendix 4E and Annual Report is available on the Company's website, www.clinuvel.com.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Media Enquiries

Monsoon Communications
Mr Rudi Michelson, 61 411 402 737, rudim@monsoon.com.au

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2024 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: mail@clinuvel.com

Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

